Pain Management for Buprenorphine Patients Undergoing Dental Procedures
Patients on buprenorphine for opioid use disorder should NOT be denied opioid analgesia for dental procedures, and buprenorphine should be continued throughout the perioperative period. Denying pain management creates unnecessary suffering and significantly increases the risk of relapse to illicit opioid use, which carries far greater morbidity and mortality than the procedural pain itself 1.
Core Management Strategy
The most recent multisociety consensus (2019) and clinical evidence strongly support continuing buprenorphine during acute pain episodes rather than discontinuing it 2. For a patient on 8 mg daily buprenorphine undergoing a dental procedure, here is the algorithmic approach:
Step 1: Continue Buprenorphine Maintenance
- Maintain the 8 mg daily dose without interruption 1
- This prevents withdrawal symptoms and maintains OUD treatment stability
- The 8 mg dose is well below the threshold where opioid blockade becomes problematic (doses >12-16 mg may require adjustment) 2
Step 2: Add Multimodal Analgesia
Build a comprehensive pain plan using:
Non-opioid analgesics (first-line):
- NSAIDs (ibuprofen 600-800 mg every 6-8 hours)
- Acetaminophen (1000 mg every 6 hours)
- Local anesthetic infiltration by the dentist 1, 2
Short-acting opioid agonists (if needed for breakthrough pain):
- Expect to use higher than typical doses due to opioid tolerance 1
- Oxycodone or hydrocodone at increased doses, titrated to effect
- The buprenorphine's high μ-receptor affinity means full agonists must compete for receptor binding, requiring dose escalation 1
Step 3: Alternative Buprenorphine Dosing Strategy
If pain control remains inadequate with the above approach, consider divided dosing of buprenorphine 1:
- Split the 8 mg daily dose into 2 mg every 6 hours
- This leverages buprenorphine's own analgesic properties at more frequent intervals
- Can be combined with additional short-acting opioids if needed
Critical Pitfalls to Avoid
DO NOT discontinue buprenorphine for a dental procedure. The evidence is clear that discontinuation:
- Places patients at extremely high risk for relapse to illicit opioid use 1, 3, 4
- Creates unnecessary barriers to OUD treatment 5
- Results in difficult re-induction onto buprenorphine after pain resolves 1
- The FDA label explicitly warns that "prohibiting or creating barriers to treatment can pose an even greater risk of morbidity and mortality due to the opioid use disorder alone" 5
DO NOT assume buprenorphine provides adequate analgesia alone at maintenance doses. While buprenorphine has analgesic properties, maintenance doses for OUD (8 mg daily) provide minimal acute pain relief and require supplementation 1.
Coordination Requirements
Contact the patient's addiction medicine provider:
- Inform them of the procedure and pain management plan 1
- Coordinate any temporary dosing adjustments
- Ensure continuity of buprenorphine prescribing during recovery
- This communication is essential for maintaining treatment engagement 3, 6
Monitor for sedation carefully if combining buprenorphine with full agonist opioids, though respiratory depression risk is lower than with full agonists alone due to buprenorphine's ceiling effect on respiratory depression 1.
Evidence Quality and Consensus Evolution
The guidelines have evolved significantly. Older recommendations (2006-2014) often suggested discontinuing buprenorphine 72 hours before procedures 2. However, more recent evidence (2018-2019) achieved 100% expert consensus that buprenorphine should be continued, especially at doses ≤12 mg daily 2. The 2019 British Journal of Anaesthesia multisociety Delphi process specifically prioritized exacerbation of underlying OUD as a primary outcome, recognizing that relapse risk outweighs concerns about analgesic efficacy 2.
The most recent research (2020-2025) consistently reinforces that adequate analgesia can be achieved while maintaining buprenorphine, and that discontinuation poses unacceptable risks to recovery 3, 6, 4, 7.